Dr. Vogelzang on Mortalities in the Cabozantinib Trial

Video

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Program at the Comprehensive Cancer Centers of Nevada discusses the 6 mortalities in the cabozantinib (XL184) phase II randomized discontinuation trial for patients with advanced solid tumors.

Related Videos
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH